Brief: Pieris Pharmaceuticals - Announced Development Of Prs- 220, For Treatment Of Idiopathic Pulmonary Fibrosis

Palvella Therapeutics

25/06/2021 12:50

June 25 (Reuters) - Pieris Pharmaceuticals Inc  PIRS.O :
    * PIERIS PHARMACEUTICALS - ANNOUNCED DEVELOPMENT OF PRS-
220, FOR
TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
    * PIERIS PHARMACEUTICALS INC - ANNOUNCED IT HAS BEEN
SELECTED TO
RECEIVE A 14.2 MILLION EURO (APPROXIMATELY 17 MILLION USD) GRANT
    * PIERIS PHARMA - GRANT INTENDED TO SUPPORT EVALUATION OF
PRS-220
IN PASC-PF BEYOND INTENDED IPF POPULATION
    * PIERIS PHARMACEUTICALS INC - INTENDS TO PRESENT
PRECLINICAL DATA
FOR PRS-220 LATER THIS YEAR

Source text for Eikon: [https://bit.ly/3vYSkRw]
Further company coverage:  PIRS.O 

 ((Reuters.Briefs@thomsonreuters.com;))